FLORHAM PARK, N.J. and NEW YORK, Jan. 8, 2021 — Celularity, Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and GX Acquisition Corp. (Nasdaq: GXGX), a special purpose acquisition company, today announced they have entered into a definitive merger agreement pursuant to which GX Acquisition Corp. will combine with Celularity. Upon the closing of the transaction, which is expected to occur in the second quarter of 2021, GX Acquisition Corp. will be renamed Celularity Inc., and its common stock and warrants are expected to remain listed on Nasdaq under the new ticker symbols “CELU” and “CELUW.” [Read more…]
Stem Cell Treatments For Macular Degeneration
Macular degeneration is a crushing condition, leading to loss of visual acuity, and in some cases, eventual blindness. Even those who don’t experience total eyesight loss suffer a frustrating degradation of central vision, which makes driving, using the computer or other devices, recognizing faces, reading and many other activities nearly impossible to do. However, recent advancements in stem cell treatments for macular degeneration are providing a beacon of hope to many. [Read more…]
The Complete Guide To Virtual Stem Cell Conferences in 2021
As the world has been rocked by the COVID-19 pandemic, most in-person conferences have been canceled or switched to online formats. This goes for stem cell conferences too. However, stem cell conferences are still happening in 2021, albeit mostly virtual.
Here is your complete guide to virtual stem cell conferences in 2021. Learn more below to decide which ones to attend. For ease of reference, they are organized by date. [Read more…]
What Is An RMAT? List of RMAT Designations (50)
To date, 50 RMAT (Regenerative Medicine Advanced Therapy) designations have been publicly announced. However, the FDA states it has received 155 requests and issued 59, which means that several are not yet public knowledge.
Sponsors of cell and gene therapies are eligible to obtain an RMAT designation from the U.S. FDA if their product is intended to treat serious or life-threatening diseases and there is preliminary clinical evidence that it can address unmet medical needs.
Thus far, only two companies (Abeona Therapeutics and Athersys) have received two RMAT designations from the U.S. FDA.
CAR-T Companies Proliferate: List of CAR-T Companies Worldwide
CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. This article provides a comprehensive list of CAR-T therapy companies worldwide. Read on to learn more about innovative CAR-T cell therapy companies and the technologies they are using to fight cancer.
In this article:
